Trials / Completed
CompletedNCT05003700
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma：a Prospective, Single-arm，Phase II Trial.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Nanfang Hospital, Southern Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin and raltitrexed plus lenvatinib and camrelizumab in patients with unresectable hepatocellular carcinoma (HCC).
Detailed description
Hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin and raltitrexed was effective and safe for hepatocellular carcinoma. Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma, and programmed cell death protein-1 (PD-1) antibody was effective and tolerable in patients with advanced hepatocellular carcinoma. No study has evaluated HAIC of oxaliplatin and raltitrexed plus lenvatinib and camrelizumab. Thus, the investigators carried out this prospective, single-arm study to find out it.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Hepatic arterial infusion chemotherapy | administration of oxaliplatin and raltitrexed via the tumor feeding arteries every 3 weeks. |
| DRUG | Lenvatinib | 8 mg once daily (QD) oral dosing. |
| DRUG | Camrelizumab | 200mg intravenously every 3 weeks. |
Timeline
- Start date
- 2021-08-12
- Primary completion
- 2023-05-26
- Completion
- 2024-07-04
- First posted
- 2021-08-12
- Last updated
- 2024-11-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05003700. Inclusion in this directory is not an endorsement.